MUC1 and cancer

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1455, Issue 2-3, 1999, Pages 301-313

  Taylor Papadimitriou, J ^a   Burchell, J ^a   Miles, D W ^a   Dalziel, M ^a  

^a IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

Author keywords

Breast cancer; Membrane mucin; O glycan immunotherapy

Indexed keywords

AMINO ACID; ANTIGEN; CARBOHYDRATE; CORE PROTEIN; CYCLOPHOSPHAMIDE; EPITOPE; GLYCAN; GLYCOSYLTRANSFERASE; MEMBRANE PROTEIN; MONOCLONAL ANTIBODY; MUCIN; PROTEIN ANTIBODY; SERINE; THREONINE;

ALLELE; ANIMAL MODEL; BREAST CANCER; CANCER; CANCER IMMUNOTHERAPY; EFFECTOR CELL; EPITHELIUM CELL; FEMALE; GLYCOSYLATION; HUMAN; IMMUNE RESPONSE; MOLECULAR CLONING; MOUSE; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; PROTEIN DOMAIN; REVIEW; TANDEM REPEAT; TRANSGENIC MOUSE;

AMINO ACID SEQUENCE; ANIMALS; BREAST NEOPLASMS; CA-15-3 ANTIGEN; CLINICAL TRIALS, PHASE I; COLONIC NEOPLASMS; GENE EXPRESSION REGULATION, NEOPLASTIC; GLYCOPROTEINS; GLYCOSYLATION; HUMANS; IMMUNOTHERAPY; MOLECULAR SEQUENCE DATA; NEOPLASMS; PEPTIDE FRAGMENTS;

EID: 0032852259     PISSN: 09254439     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0925-4439(99)00055-1     Document Type: Review

References (90)

1. Shimiza M., Yamauchi K. Isolation and characterisation of mucin-like glycoprotein in human milk fat globule membrane. J. Biochem. 91:1982;515-524.
2. Taylor-Papadimitriou J. Report on the First International Workshop on Carcinoma-associated Mucins. Int. J. Cancer. 49:1991;1-5.
3. ISOBM TD-4 International Workshop on Monoclonal Antibodies against MUC1, in: P.D. Rye, M.R. Price (Eds.), Tumor Biology, Karger, Basle, 1998, pp. 1-152.
4. Burchell J., Taylor-Papadimitriou J., Boshell M., Gendler S., Duhig T. A short sequence, within the amino acid tandem repeat of a cancer-associated mucin, contains immunodominant epitopes. Int. J. Cancer. 44:1989;691-696.
5. Xing P.X., Prenzoska J., McKenzie I.F. Epitope mapping of anti-breast and anti-ovarian mucin monoclonal antibodies. Mol. Immunol. 29:1992;641-650.
6. Briggs S., Price M.R., Tendler S.B.J. Fine specificity of antibody recognition of breast carcinoma-associated epithelial mucins: antibody binding to synthetic peptide epitopes. Eur. J. Cancer. 29A:1993;230-237.
7. Zotter S., Hageman P.C., Lossnitzer A., Mooi W.J., Hilgers J. Tissue and tumour distribution of human polymorphic epithelial mucin. Cancer Rev. 11-12:1988;55-101.
8. Girling A., Bartkova J., Burchell J., Gendler S.J., Gillett C., Taylor-Papadimitriou J. A core protein epitope of the PEM mucin detected by the monoclonal antibody SM-3 is selectively exposed in a range of primary carcinomas. Int. J. Cancer. 43:1989;1072-1076.
9. Burdick M.D., Harris A., Reid C.J., Iwamura T., Hollingsworth M.A. Oligosaccharides expressed on MUC1 produced by pancreatic and colon tumour cell lines. J. Biol. Chem. 272:1997;24198-24202.
10. Zhang S., Zhang H.S., Reuter V.E., Slovin S.E., Scher H.I., Livingston P.O. Expression of potential target antigens for immunotherapy on primary and metastatic prostate cancers. Clin. Cancer Res. 4:1998;295-302.
11. Burchell J., Taylor-Papadimitriou J. Effect of modification of carbohydrate side chains on the reactivity of antibodies with core protein epitopes of the MUC1 gene product. Epithel. Cell Biol. 2:1993;155-162.
12. Burchell J., Gendler S.J., Taylor-Papadimitriou J., Girling A., Lewis A., Millis R., Lamport D. Development and characterisation of breast cancer reactive monoclonal antibodies directed to the core protein of the human milk mucin. Cancer Res. 47:1987;5476-5482.
13. Cao Y., Blohm D., Ghadimi B.M., Stosiek P., Xing P.-X., Karsten U. Mucins (MUC1 and MUC3) of gastrointestinal and breast epithelia reveal different and heterogeneous tumour-associated aberrations in glycosylation. J. Histochem. Cytochem. 45:1997;1547-1557.
14. Gendler S.J., Lancaster C.A., Taylor-Papadimitriou J., Duhig T., Peat N., Burchell J., Pemberton L., Lalani E.-N., Wilson D. Molecular cloning and expression of human tumour-associated polymorphic epithelial mucin. J. Biol. Chem. 265:1990;15286-15293.
15. Lan M.S., Batra S.K., Qi W.-N., Metzgar R.S., Hollingsworth M.A. Cloning and sequencing of a human pancreatic tumour mucin cDNA. J. Biol. Chem. 265:1990;15294-15299.
16. Gum J.R.J. Mucin genes and the proteins they encode: structure, diversity, and regulation. Am. J. Respir. Cell Mol. Biol. 7:1992;557-564.
17. Nollet S., Moniaux N., Maury J., Petitprez D., Degand P., Laine A., Porchet N., Aubert J.P. Human mucin gene MUC4: organisation of its 5′-region and polymorphism of its central tandem repeat array. Biochem. J. 332:1998;739-748.
18. Carraway K.L., Fregien N., Carraway K.L.D., Carraway C.A. Tumour sialomucin complexes as tumour antigens and modulators of cellular interactions and proliferation. J. Cell Sci. 103:1992;299-307.
19. Swallow D.M., Gendler S., Griffiths B., Corney G., Taylor-Papadimitriou J., Bramwell M.E. The human tumour-associated epithelial mucins are coded by an expressed hypervariable gene locus PUM. Nature. 328:1987;82-84.
20. Spicer A.P., Parry G., Patton S., Gendler S.J. Molecular cloning and analysis of the mouse homologue of the tumour-associated mucin, MUC1, reveals conservation of potential O-glycosylation sites, transmembrane, and cytoplasmic domains and a loss of minisatellite-like polymorphism. J. Biol. Chem. 266:1991;15099-15109.
21. Zrihan-Licht S., Vos H.L., Baruch A., Elroy-Stein O., Sagiv D., Keydar I., Hilkens J., Wreschner D.H. Characterisation and molecular cloning of a novel MUC1 protein, devoid of tandem repeats, expressed in human breast cancer tissue. Eur. J. Biochem. 224:1994;787-795.
22. Brockhausen, I. (1996). The biosynthesis of O-glycosylprotein, in: J. Montreuil, J.F.G. Vliegenthart, H. Schachter (Eds.), New Comprehensive Biochemistry. Glycoproteins, Elsevier, Amsterdam, 29a, pp. 201-259.
23. Wandall H.H., Hassan H., Mirgorodskaya K., Kristensen A.K., Roepstorff P., Bennett E.P., Nielsen P.A., Hollingsworth M.A., Burchell J., Taylor-Papadimitriou J., Clausen H. Substrate specificities of three members of the human UDP-N-Acetyl-a-D-galactosamine: polypeptide N-acetylgalactosaminyltransferase family, GalNAc-T1, - T2, and -T3. J. Biol. Chem. 272:1997;23503-23514.
24. Rottger S., White J., Wandall H.H., Olivo J.-C., Stark A., Bennett E.P., Whitehouse C., Berger E.G., Clausen H., Nilsson T. Localisation of three human polypeptide GalNAc-transferases in HeLa cells suggests initiation of O-linked glycosylation throughout the Golgi apparatus. J. Cell Sci. 111:1998;45-60.
25. Gerken T.A., Owens C.L., Pasumarthy M. Determination of the site-specific O-glycosylation pattern of the porcine submaxillary mucin tandem repeat glycopeptide. Model proposed for the polypeptide:GalNAc transferase peptide binding site. J. Biol. Chem. 272:1997;9709-9719.
26. Muller S., Goletz S., Packer N., Gooley A., Lawson A.M., Hanisch F.-G. Localisation of O-glycosylation sites on glycopeptide fragments from lactation-associated MUC1. J. Biol. Chem. 272:1997;24780-24793.
27. Hanisch F.-G., Uhlenbruck G., Peter-Katalinic J., Egge H., Dabrowski J., Dabrowski U. Structures of neutral O-linked polylactosaminoglycans on human skim milk mucins. A novel type of linearly extended poly-N-acetyllactosamine backbones with Galbeta(1-4)GlcNAc beta(1-6) repeating units. J. Biol. Chem. 264:1989;872-873.
28. Hanisch F.-G., Peter-Katalinic J., Egge H., Dabrowski U., Uhlenbruck G. Structures of acidic O-linked polylactosaminoglycans on human skim milk mucins. Glycoconjugate J. 7:1990;524-525.
29. Lloyd K.O., Burchell J., Kudryashov V., Yin B.W.T., Taylor-Papadimitriou J. Comparison of O-linked carbohydrate chains in MUC-1 mucin from normal breast epithelial cell lines and breast carcinoma cell lines. J. Biol. Chem. 271:1996;33325-33334.
30. Hull S.R., Bright A., Carraway K.L., Abe M., Hayes D.F., Kufe D.W. Oligosaccharide differences in the DF3 sialomucin antigen from normal human milk and the BT-20 human breast carcinoma cell line. Cancer Commun. 1:1989;261-267.
31. Pemberton L., Taylor-Papadimitriou J., Gendler S.R. Antibodies to the cytoplasmic domain of the MUC1 mucin show conservation throughout mammals. Biochem. Biophys. Res. Commun. 185:1992;167-175.
32. Springer G.F. Immunoreactive T and Tn epitopes in cancer diagnosis, prognosis, and immunotherapy. J. Mol. Med. 75:1997;594-602.
33. Brockhausen I., Yang J.M., Burchell J., Whitehouse C., Taylor-Papadimitriou J. Mechanisms underlying aberrant glycosylation of MUC1 mucin in breast cancer cells. Eur. J. Cancer. 233:1995;607-617.
34. Sekine M., Kiyomitsu N., Suzuki A. Tissue-specific regulation of mouse core 2 β-1,6-N-Acetylglucosaminyltransferase. J. Biol. Chem. 272:(43):1997;27246-27252.
35. Bierhuizen M.F.A., Fukuda M. Expression cloning of a cDNA encoding UDP-GlcNAc:Galβ1-3-GalNAc-R (GlcNAc to GalNAc) β1-6GlcNAc transferase by gene transfer into CHO cells expressing polyoma large tumour antigen. Proc. Natl. Acad. Sci. USA. 89:1992;9326-9330.
36. Kuhns W., Rutz V., Paulsen H., Matta K.L., Baker M.A., Barner M., Granovsky M., Brockhausen I. Processing of O-glycan core 1, Galβ1-3 GalNAcα-R. Specificities of core 2 UDP-GlcNAc: GalGb1-3 GalNAc-R β6-N-acetylglucosaminyltransferase and CMP-sialic acid: Galβ1-3 GalNAc-R α3-sialytransferase. Glycoconjugate J. 10:1993;381-394.
37. Chang M.L., Eddy R.L., Shous T.B., Lau J.T.Y. Three genes encode human β-galactoside α2-3 siayltransferases. Structural analysis and chromosomal mapping studies. Glycobiology. 5:1995;319-325.
38. Giordanengo V., Bannwarth S., Laffont C., Van Miegem V., Harduin-Lepers A., Delannoy P., Lefebvre J.-C. Cloning and expression of cDNA for a human Gal(β1-3)GalNAc α2,3-sialyltransferase from the CEM T-cell line. Eur. J. Biochem. 247:1997;558-566.
39. J. Burchell, R. Poulsom, A. Hanby, C. Whitehouse, L. Cooper, D. Miles, J. Taylor-Papadimitriou, An α2,3 sialyltransferase (ST3 Gal1) is elevated in primary breast carcinomas, Cancer Res., submitted for publication.
40. Whitehouse C., Burchell J., Gschmeissner S., Brockhausen I., Lloyd K., Taylor-Papadimitriou J. Golgi localisation of an O-linked glycosyltransferase, α2,3 sialytransferase, which is elevated in breast carcinomas. J. Cell Biol. 137:1997;1229-1241.
41. Yang J.M., Byrd J.C., Siddiki B.B., Chung Y.S., Okuno M., Sowa M., Kim Y.S., Matta K.L., Brockhausen I. Alterations of O-glycan biosynthesis in human colon cancer tissues. Glycobiology. 4:(6):1994;873-884.
42. Zhang K., Baeckstrom D., Brevinge H., Hansson G.C. Secreted MUC1 mucins lacking their cytoplasmic part and carrying sialyl-Lewis a and x epitopes from a tumour cell line and sera of colon carcinoma patients can inhibit HL-60 leukocyte adhesion to E-selectin-expressing endothelial cells. J. Cell. Biochem. 60:1996;538-549.
43. Reis C.A., David L., Sixas M., Burchell J., Sobrinho-Simoes M. Expression of fully and under-glycosylated forms of MUC1 mucin in gastric carcinoma. Int. J. Cancer. 79:1998;1-9.
44. Mann B., Klussmann E., Vandamme-Feldhaus V., Iwersen M., Hanski M.L., Riecken E.O., Buhr H.J., Schauer R., Kim Y.S., Hanski C. Low O-acetylation of sialyl-Le(x) contributes to its overexpression in colon carcinoma metastases. Int. J. Cancer. 72:1997;258-264.
45. Ligtenberg M.J.L., Buijs F., Vos H.L., Hilkens J. Suppression of cellular aggregation by high levels of episialin. Cancer Res. 52:1992;2318-2324.
46. Wesseling J., Van der Valk S.W., Vos H.L., Sonnenberg A., Hilkens J. Episialin (MUC1) overexpression inhibits integrin-mediated cell adhesion to extracellular matrix components. J. Cell Biol. 129:1995;255-265.
47. Wesseling J., van der Valk S.W., Hilkens J. A mechanism for inhibition of E-cadherin-mediated cell-cell adhesion by the membrane-associated mucin episialin/MUC1. Mol. Biol. Cell. 7:1996;565-577.
48. Yamamoto M., Bharti A., Li Y., Kufe D. Interaction of the DF3/MUC1 breast carcinoma-associated antigen and β-catenin in cell adhesion. J. Biol. Chem. 272:1997;12492-12494.
49. Regimbald L.H., Pilarski L.M., Longenecker B.M., Reddish M.A., Zimmermann G., Hugh J.C. The breast mucin MUC1 as a novel adhesion ligand for endothelial intercellular adhesion molecule 1 in breast cancer. Cancer Res. 56:1996;4244-4249.
50. Bohm C.M., Mulder M.C., Zennadi R., Notter M., Schmitt-Graff A., Finn O.J., Taylor-Papadimitriou J., Stein H., Clausen H., Riecken E.O., Hanski C. Carbohydrate recognition on MUC1-expressing targets enhances cytotoxicity of a T cell subpopulation. Scand. J. Immunol. 46:1997;27-34.
51. P. Nath, A. Hartnell, L. Happerfield, D.W. Miles, J. Burchell, J. Taylor-Papadimitriou, P.R. Crocker, Macrophage-tumour cell interactions: identification of MUC1 on breast cancer cells as a potential counter-receptor for the macrophage-restricted receptor, sialoadhesin, Immunology, in press.
52. Spicer A.P., Rowse G.J., Lidner T.K., Gendler S.J. Delayed mammary tumour progression in Muc-1 Null mice. J. Biol. Chem. 270:1995;30093-30101.
53. Medzhitov R., Janeway C.A. Innate immunity: the virtues of a nonclonal system of recognition. Cell. 91:1997;295-298.
54. Chu R.S., Targoni O.S., Krieg A.M., Lehmann P.V., Harding C.V. CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunity. J. Exp. Med. 186:1997;1623-1631.
55. Barnd D.L., Lan M.S., Metzgar R.S., Finn O.J. Specific, major histocompatibility complex-unrestricted recognition of tumour-associated mucins by human cytotoxic T cells. Proc. Natl. Acad. Sci. USA. 86:1989;7159-7163.
56. Jerome K.R., Barnd D.L., Bendt K.M., Boyer C.M., Taylor-Papadimitriou J., McKenzie I.F.C., Basr R.C.J., Finn O.J. Cytotoxic T-lymphocytes derived from patients with breast adenocarcinoma recognise an epitope present on the protein core of a mucin molecule preferentially expressed by malignant cells. Cancer Res. 51:1991;2908-2916.
57. Finn O.J., Jerome K.R., Henderson R.A., Pecher G., Domenech N., Magarian-Blander J., Barratt-Boyes S.M. MUC-1 epithelial tumour mucin-based immunity and cancer vaccines. Immunol. Rev. 145:1995;61-89.
58. Gourevitch M.M., Von Mensdorff-Pouilly S., Litvinov S.V., Kenemans P., Van Kamp G.J., Verstraeten A.A., Hilgers J. Polymorphic epithelial mucin (MUC-1)-containing circulating immune complexes in carcinoma patients. Br. J. Cancer. 72:1995;934-938.
59. von Mensdorff-Pouilly S., Gourevitch M.M., Kenemans P., Verstraeten A.A., van Kamp G.J., Kok A., van Uffelen K., Snijdewint F.G., Paul M.A., Meijer S., Hilgers J. An enzyme-linked immunosorbent assay for the measurement of circulating antibodies to polymorphic epithelial mucin (MUC1). Tumour Biol. 19:1998;186-195.
60. Apostolopoulos V., Loveland B.E., Pietersz G.A., McKenzie I.F.C. CTL in mice immunised with human mucin1 are MHC-restricted. J. Immunol. 155:1995;5089-5094.
61. Apostolopoulos V., Karanikas V., Haurum J.S., McKenzie I.F.C. Induction of HLA-A2-restricted CTLs to the mucin 1 human breast cancer antigen. J. Immunol. 159:1997;5211-5218.
62. Domenech N., Henderson R.A., Finn O.J. Identification of an HLA-A11-restricted epitope from the tandem repeat domain of the epithelial tumour antigen mucin. J. Immunol. 155:1995;4766-4774.
63. Agrawal B., Reddish M.A., Longenecker B.M. In vitro induction of MUC-1 peptide-specific type 1 T lymphocyte and cytotoxic T lymphocyte responses from healthy multiparous donors. J. Immunol. 157:1996;2089-2095.
64. Agrawal B., Krantz M.J., Reddish M.A., Longenecker B.M. Cancer-associated MUC1 mucin inhibits human T-cell proliferation, which is eversible by IL-2. Nat. Med. 4:1998;43-49.
65. van de Wiel-van Kemenade E., Ligtenberg M.J., de Boer A.J., Buijs F., Vos H.L., Melief C.J., Hilkens J., Figdor C.G. Episialin (MUC1) inhibits cytotoxic lymphocyte-target cell interaction. J. Immunol. 151:1993;767-776.
66. Maraveyas A., Snook D., Hird V., Kosmas C., Meares C.F., Lambert H.E., Epenetos A.A. Pharmacokinetics and toxicity of an yttrium-90-CITC-DTPA-HMFG1 radioimmuno-conjugate for intraperitoneal radioimmunotherapy of ovarian cancer. Cancer. 73:1994;1067-1075.
67. Riethmuller G., Schneider-Gadicke E., Schlimok G., et al. Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes' C colorectal carcinoma. Lancet. 343:1994;1177-1183.
68. Kramer E.L., DeNardo S.J., Liebes L., Kroger L.A., Noz M.E., Mizrachi H., Salako Q.A., Furmanski P., Glenn S.D., DeNardo G.L. Radioimmunolocalisation of metastatic breast carcinoma using indium-111-methyl benzyl DTPA BrE-3 monoclonal antibody: phase I study. J. Nuclear Med. 34:1993;1067-1074.
69. DeNardo S.J., Kramer E.L., O'Donnell R.T., Richman C.M., Salako Q.A., Shen S., Noz M., Glenn S.D., Ceriani R.L., DeNardo G.L. Radioimmunotherapy for breast cancer using indium-111-yttrium-90 BrE-3: results of a phase I clinical trial. J. Nuclear Med. 38:1997;1180-1185.
70. 99mTc-labelled SM3 in the preoperative evaluation of axillary lymph nodes and primary breast cancer with change detection statistical processing as an aid to tumour detection. Br. J. Cancer. 77:1998;131-138.
71. Graham R.A., Burchell J.M., Beverley P., Taylor-Papadimitriou J. Intramuscular immunisation with MUC1 cDNA can protect C57 mice challenged with MUC1 expressing syngeneic mouse tumour cells. Int. J. Cancer. 65:1996;664-670.
72. Peat N., Gendler S.J., Lalani E.-N., Duhig T., Taylor-Papadimitriou J. Tissue-specific expression of a human polymorphic epithelial mucin (MUC1) in transgenic mice. Cancer Res. 52:1992;1954-1960.
73. Rowse G.J., Tempero R.M., VanLith M.L., Hollingsworth M.A., Gendler S.J. Tolerance and immunity to MUC1 in human MUC1 transgenic murine model. Cancer Res. 58:1998;315-321.
74. Acres R., Hareuveni M., Balloul J., Kieny M. Vaccinia virus MUC1 immunisation of mice: immune response and protection against the growth of murine tumours bearing the MUC1 antigen. J. Immunother. 14:1993;136-143.
75. Ding L., Lalani E.-N., Reddish M., Koganty R., Wong T., Samuel J., Yacyshyn M.B., Meikle A., Fung P.Y.S., Taylor-Papadimitriou J., Longenecker B.M. Immunogenicity of synthetic peptides related to the core peptide sequence encoded by the human MUC1 mucin gene: effect of immunisation on the growth of murine mammary adenocarcinoma cells transfected with the human MUC1 gene. Cancer Immunol. Immunother. 36:1993;9-17.
76. Samuel J., Budzynski W.A., Reddish M.A., Ding L., Zimmermann G.L., Krantz M.J., Koganty R.R., Longenecker B.M. Immunogenicity and antitumour activity of a liposomal MUC1 peptide-based vaccine. Int. J. Cancer. 75:1998;295-302.
77. Smith M., Burchell J.M., Graham R., Cohen E.P., Taylor-Papadimitriou J. Expression of B7.1 in a MUC1 expressing mouse mammary epithelial tumour cell line overcomes tolerance but does not induce autoimmunity in MUC1 transgenic mice. Immunology. 97:1999;648-655.
78. Gong J., Chen D., Kashiwaba M., Li Y., Chen L., Takeuchi H., Qu H., Rowse G.J., Gendler S.J., Kufe D. Reversal of tolerance to human MUC1 antigen in MUC1 transgenic mice immunised with fusions of dendritic and carcinoma cells. Proc. Natl. Acad. Sci. USA. 95:1998;6279-6283.
79. Xing P.-X., Michael M., Apostolopoulos V., Prenzoska J., Marshall C., Bishop J., McKenzie I. Phase I study of synthetic MUC1 peptides in breast cancer. Int. J. Oncol. 6:1995;1283-1289.
80. Goydos J., Elder E., Whiteside T., Finn O., Lotze M. A phase I trial of a synthetic mucin peptide vaccine. Induction of specific immune reactivity in patients with adenocarcinoma. J. Surg. Res. 63:1996;298-304.
81. Reddish M.A., MacLean G.D., Koganty R.R., Kan-Mitchell J., Jones V., Mitchell M.S., Longenecker B.M. Anti-MUC1 class I restricted CTLs in metastatic breast cancer patients immunised with a synthetic MUC1 peptide. Int. J. Cancer. 76:1998;817-823.
82. Apostolopoulos V., Pietersz G., Loveland B., Sandrin M., McKenzie I. Oxidative/reductive conjugate of mannan to antigen selects for Th1 and Th2 immune responses. Proc. Natl. Acad. Sci. USA. 92:1995;10128-10132.
83. Karanikas V., Hwang L.A., Pearson J., Ong C.S., Apostolopoulos V., Vaughan H., Xing P.X., Jamieson G., Pietersz G., Tait B., Broadbent R., Thynne G., McKenzie I.F. Antibody and T cell responses of patients with adenocarcinoma immunised with mannan-MUC1 fusion protein. J. Clin. Invest. 100:1997;2738-2792.
84. Apostolopoulos V., Osinski C., McKenzie I.F.C. MUC1 cross-reactive Galα(1,3)Gal antibodies in humans switch immune responses from cellular to humoral. Nature Med. 4:1998;315-320.
85. Balloul J., Acres R., Geist M., Dott K., Stefani L., Schmitt D., Drillien R., Spehner D., McKenzie I., Xing P. Recombinant MUC1 vaccinia virus: a potential vector for immunotherapy of breast cancer. Cell. Mol. Biol. 40:1994;49-59.
86. S. Scholl, B. Acres, C. Schatz, M.P. Kieny, J.M. Balloul, A. Vincent-Salomon, L. Deneux, E. Tartour, H. Fridman, P. Pouillart, The polymorphic epithelial mucin (MUC1): a phase I clinical trial testing the tolerance and immunogenicity of a vaccinia virus-MUC1-IL2 construct in breast cancer, Breast Cancer Res. Treat., 67 (1997) Abstract 268.
87. MacLean G.D., Reddish M.A., Koganty R.R., Longenecker B.M. Antibodies against mucin-associated sialyl-Tn epitopes correlate with survival of metastatic adenocarcinoma patients undergoing active specific immunotherapy with synthetic STn vaccine. J. Immunother. 19:1996;59-68.
88. MacLean G., Miles D., Rubens R., Reddish M., Longenecker B. Enhancing the effect of THERATOPE STn-KLH cancer vaccine patients with metastatic breast cancer by pre-treatment with low-dose intravenous cyclophosphamide. J. Immunother. 19:1996;309-316.
89. Fung P., Madej M., Koganty K., Longenecker B. Active specific immunotherapy of a murine mammary adenocarcinoma using a synthetic tumour-associated glycoconjugate. Cancer Res. 50:1990;4308-4314.
90. Singhal A., Fohn M., Hakomori S.-I. Induction of α-N-acetylgalactosamine-O-serine/threonine (Tn) antigen-mediated cellular immune response for active immunotherapy in mice. Cancer Res. 51:1991;1406-1411.